Checkmate Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is focused on developing and commercializing its technology to harness the power of the immune system to combat cancer. The Company’s product candidate, CMP-001 is a Toll-like receptor 9 (TLR9) agonist delivered as a biologic virus-like particle (VLP) utilizing a CpG-A oligonucleotide as a key component. CMP-001 is based on a therapeutic approach, which consists of two components, a capsid protein, which is produced by fermentation, and is derived from a QBeta Ribonucleic acid (RNA) bacteriophage; and a CpG-A deoxyribonucleic acid (DNA) oligonucleotide, which is manufactured by solid phase synthesis. These two components are combined together under controlled conditions where they self-assemble to form the VLP.